Adjuvant chemotherapy in stage IB NSCLC: Implication of the new TNM staging system

被引：2
作者：
Dediu M. [1 ]
机构：
[1] Medical Oncology Department, Institute of Oncology Alexandru Trestioreanu, 022328 Bucharest
来源：
memo - Magazine of European Medical Oncology | 2011年 / 4卷 / 1期
关键词：
Adjuvant chemotherapy; NSCLC; Stage IB; TNM classification;
D O I：
10.1007/s12254-011-0239-6
中图分类号：
学科分类号：
摘要：
Adjuvant chemotherapy (CT) became the standard of care for patients with completely resected non-small cell lung cancer. However, the evidence supports this intervention for stages II-IIIA only. For stage IB, the randomized trials were not able co configure a clear-cut conclusion. Positive results have been published by the Japanese investigators using uracil-tegafur, whereas no survival benefit was observed in the trials using platinum-based CT. The new TNM staging system adopted in 2009 operated some modifications which partially included the former stage IB. Despite the fact that the new staging system is currently in use, the recommendations regarding adjuvant CT, as they appear in the guidelines, are based on the evidence built on the previous TNM classification. Subsequently, the issue regarding adjuvant CT in stage IB deserves a new perspective. This paper will address the new viewpoint regarding adjuvant CT in stage IB, defined according to the current evidence and the amendments of new TNM staging system. © 2011 Springer.
引用
收藏
页码：16 / 18
页数：2
相关论文
共 21 条
  • [1] Crino L., Weder W., Van Meerbeeck J., Et al., Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice. Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 21, SUPPL. 5, (2010)
  • [2] Pisters K.M.W., Evans W.K., Azzoli C.G., Kris M.G., Smith C.A., Desch C.E., Somerfield M.R., Brouwers M.C., Darling G., Ellis P.M., Gaspar L.E., Pass H.I., Spigel D.R., Strawn J.R., Ung Y.C., Shepherd F.A., Cancer Care Ontario and American Society of clinical oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non-small-cell lung cancer guideline, Journal of Clinical Oncology, 25, 34, pp. 5506-5518, (2007)
  • [3] Scagliotti G.V., Fossati R., Torri V., Crino L., Giaccone G., Silvano G., Martelli M., Clerici M., Cognetti F., Tonato M., Liguori G., Nittolo G., Vasta M., Curcio C., Borasio P., Dogliotti L., Scagliotti G.V., Angeletti C.A., Conte P.F., Laddaga M., Rebecchini S., Spagnesi S., Lewinski T., Salvati F., De Marinis F., Altieri A., Giordano F., Puglisi G., Cipriani A., Favaretto A., Fiorentino M., Giampaglia G., Loreggian L., Zuin R., Jassem J., Ukmar R., Buffoni A., Puricelli C., Talmassons G., M
  • [4] Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.-P., Vansteenkiste J., Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer, New England Journal of Medicine, 350, 4, pp. 351-360, (2004)
  • [5] Douillard J.-Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzales-Larriba J.L., Grodzki T., Pereira J.R., Le Groumellec A., Lorusso V., Clary C., Torres A.J., Dahabreh J., Souquet P.-J., Astudillo J., Fournel P., Artal-Cortes A., Jassem J., Koubkova L., His P., Riggi M., Hurteloup P., Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A rand
  • [6] Butts C., Ding K., Seymour L., Et al., Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared with Observation in Completely Resected Stage IB and II Non-Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10, J Clin Oncol, 28, pp. 29-34, (2010)
  • [7] Pignon J., Tribodet H., Scagliotti G., Et al., Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group, J Clin Oncol, 26, pp. 3552-3559, (2008)
  • [8] Strauss G., Herndon J., Maddaus M., Et al., Adjuvant Paclitaxel Plus Carboplatin Compared with Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups, J Clin Oncol, 26, pp. 5043-5051, (2008)
  • [9] Goldstraw P., Crowley J., Chansky K., Giroux D.J., Groome P.A., Rami-Porta R., Postmus P.E., Rusch V., Sobin L., The IASLC lung cancer staging project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours, Journal of Thoracic Oncology, 2, 8, pp. 706-714, (2007)
  • [10] Detterbeck F., Boffa D., Tanoue L., Et al., The new lung cancer staging System, Chest, 136, pp. 260-271, (2009)
123